Breast cancer is the leading cause of cancer death am ong wom en around the world and its incidence is annually increasing. The vitam in D receptor (VDR) gene is a m em ber of the nuclear receptor superfam ily, w hich is expressed in breast tissue and know n to m odulate the rate of cell proliferation. Association betw een the VDR gene polym orphisms and cancer developm ent has been suggested by several studies. How ever, the relationship betw een VDR polym orphism s and breast cancer is controversial and has not been confirm ed by all studies. The purpose of this study w as to investigate the genotype frequencies and association of the VDR Bsm I and Taq I polym orphism s w ith breast cancer in Turkish patients. In this study, 78 patients w ith breast cancer and 27 healthy individuals w ere enrolled. The prevalence of the VDR Taq I and Bsm I alleles and the genotype frequencies in patients w ith breast cancer w as sim ilar to that in the norm al population. O ur data indicate that no significant differences exist between the patients and control subjects.
Introduction
Breast cancer is a heterogeneous disease regarding its morphology, invasive behavior, metastatic capacity, hormone receptor expression and clinical outcome. 10-15% of breast cancer cases have some family history of the disease but only 5% can be explained by rare highly penetrant mutations in genes such as BRCA1 and BRCA2. Although some of the familial risk may be due to the shared environment, there may be other common, low-penetrance genetic variants which alter the predisposition to breast cancer. Endogenous hormone exposure is known to affect breast cancer susceptibility and genes responsive to such hormones are plausible candidates for predisposition genes (Pharoah et al., 1997) .
The steroid hormone 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) binds the vitamin D receptor (VDR) and the ligand/receptor complex regulates transcription of the genes involved in cell cycle, apoptosis and differentiation (Simboli-Campbell et al., 1996) . In the normal mammary gland, 1,25(OH)2D3 may function to regulate calcium transport during lactation or may act in concert with other hormones to maintain mammary cell differentiation and milk protein production (Bhattacharjee et al., 1987; Mezzetti et al., 1988) . Dysregulation of VDR-mediated gene expression would alter mammary gland development or function and possibly predispose cells to transformation (Buras et al., 1994) .
The VDR gene is located on the long arm of chromosome 12 (12q12-14) and is composed of 10 exons, the first of which is not transcribed (Tokita et al., 1996) . A series of common polymorphisms in the vitamin D receptor gene were recently reported be associated with both circulating levels of active vitamin D and in vitro measures of gene expression (Morrison et al., 1992) . Three of these polymorphisms can be distinguished by digestion with restriction enzymes (Hustmyer et al., 1993) . The presence or absence of a restriction site defines the specific allele. None of these polymorphisms change the translated protein. The Bsm I and Apa I polymorphisms are located in intron 8 of the VDR gene (Baker et al., 1988; Morrison et al., 1994) . The Taq I polymorphism is located in exon 9 but leads to a silent codon change, with ATT and ATC both coding for isoleucine (Farrow, 1994) .
Allelic variations of the VDR gene have been associated with the risk of osteoporosis in postmenopausal women (Jorgensen et al., 1996) and prostate cancer in men (Ingles et al., 1997) . Presence of the tt genotype has been found to be less frequent in prostate cancer patients. Therefore, it has been suggested that the t allele might protect against prostate cancer (Taylor et al., 1996) . In breast cancer, low vitamin D levels in serum are correlated with disease progression and bone metastases, a situation also
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noted in prostate tumors and suggesting involvement of the VDR gene in breast carcinogenesis (Mawer et al., 1997) . However, the relationship between VDR polymorphisms and breast cancer is controversial (Ingles et al., 2000; Hou et al., 2002) .
The purpose of this study was to investigate the association of the VDR gene Taq I and Bsm I polymorphisms with breast cancer.
M aterials and M ethods
Blood samples were obtained from 78 breast cancer patients and 27 healthy subjects. DNA for molecular analysis was isolated using standard procedures.
PCR amplification followed by restriction enzyme digestion was used to investigate the two (Taq I and Bsm I) polymorphisms at the VDR locus using 10 pmol each of the forward and reverse primers and 10 µl of amplification product was then digested with 10 U Taq I (MBI, Fermentas, Lithuania) or 2.5 U of Bsm I (Promega) for at least 3 h at 65 o C and 37 o C, respectively. The digestion products were subjected to electrophoresis on 2% agarose gels for 1 h at 100 V. The gels were evaluated in the video gel documentation system (Vilber-Lourmat, Cedex, France) using the BIOPROFIL 1D software and printed using the SONY UP 890 video graphic printer.
The χ 2 test was used to evaluate the variations of the genotype frequencies among the cases and the controls. The Odds ratios and the confidence intervals were calculated as an estimate of the relative risk. SPSS 7.5 professional statistics analysis (SPSS, Chicago) was used for the statistical calculations.
R esults
The Bsm I and Taq I polymorphisms in the VDR gene were investigated by PCR-RFLP analysis in breast cancer patients. We also genotyped 27 healthy individuals as the control group. The frequencies of the alleles and the genotypes were in Hardy-Weinberg equilibrium among the patients and the controls.
The size of the PCR product for the Bsm I polymorphism was 825 bp. Following digestion two restriction fragments of 650 bp and 175 bp were observed for bb homozygotes. A single 825 bp band was obtained for BB homozygotes. Heterozygote individuals displayed all three bands (Figure 1) . 57.7% of the patients were heterozygous for the Bsm I polymorphism, 19.3% were homozygous BB and 23% were homozygous bb. The respective frequencies in the control group were 63%, 18.5% and 18.5%. These frequencies are not significantly different from those in the breast cancer patients (χ 2 = 0.28997, P = 0.86, df = 2). The frequencies of the B and b alleles were equal in both groups. The allelic and genotypic frequencies in the patients and controls for the Bsm I polymorphism are shown in Table 1 . The size of the reaction product for the Taq I polymorphism was 740 bp, which on digestion with Our study revealed no significant differences in the prevalence of the alleles and the genotypes in the patients and the control group. In our study group, the genotype frequencies were 33.3% vs. 14.8% TT, 56.4% vs. 74.0% Tt and 10.3% vs. 11.2% tt in the breast cancer patients and the controls, respectively. We observed the t allele in 38.5% and 48%, and the T allele in 61.5% and 52.0% in the patients and the control group, respectively. (χ 2 = 3.37, P = 0.18, df = 2). The frequencies of Taq I genotypes and alleles were not significantly different in the patients and the controls (χ 2 = 1.56, P = 0.2, df = 2) ( Table 2 ). Our data indicate that, polymorphisms in the VDR gene do not affect breast cancer susceptibility.
D iscussion
There are substantial numbers of reports that have investigated candidate genes for breast cancer susceptibility. Breast cancer risk is strongly related to endogenous hormone exposure and genes responsive to such hormones are therefore plausible candidates for being susceptibility genes. The VDR is a member of the steroid hormone receptor superfamily and regulates gene transcription through interaction with hormone response elements in the promoter region of target genes (Christakos et al., 1996) . The presence of VDR in breast cancer has been documented both in cell lines (Demirpence et al., 1994; James et al., 1994; Vink-van Wijngaarden et al., 1994; LoveSchimenti et al., 1996) and in tumor samples (Swedish Breast Cancer Cooperative Group, 1996) . Both the 5' and 3'ends of the VDR gene are polymorphic. A polymorphism in the first of the two possible translation start codons produces variants differing in size and activity (Miyamoto et al., 1997) . Allelic variation in the 3' end of the VDR gene, although less clearly related to its function, appears to have phenotypic consequences for the calcium (Dawson-Hughes et al., 1995; Wishart et al., 1997) and vitamin D metabolism (Morrison et al., 1994; Ma et al., 1998) , bone mineral density (Morrison et al., 1998) and osteoporosis (Ingles et al., 1997a) , while the 5' polymorphisms are involved in peak bone density (Harris et al., 1997) .
The TaqI polymorphisms have been investigated most frequently in prostate cancer and presence of the T alleles has been associated with increased prostate cancer risk. However, the issue is still controversial since there are also reports that do not confirm such an association. Studies investigating VDR polymorphisms in breast cancer are rare and inconsistent. Two studies (Ruggiero et al., 1998; Ingles et al., 2000) have revealed a 4-fold higher risk of metastatic spread in breast cancer patients carrying the BsmI restriction site in the VDR gene. Bretherton-Watt et al. (2001) also reported an association between the bb genotype and grade II and III tumors. On the other hand, an association between the bb allele and breast cancer has been refuted in other reports (Mocherla et al., 1997; Gross et al., 1998; Hou et al., 2002) . In our study, no difference in the frequency of the b allele was observed in the breast cancer group. Statistical analysis did not reveal any significant difference in the prevalance of the BsmI polymorphism in breast cancer patients when compared with controls. Genotype frequencies were also similar in women with breast cancer and in the control population. Our data are consistent with reports on breast (Schndorf et al., 2003) and prostate cancer (Ma et al., 1998; Suzuki et al., 2003) .
It has been reported that individuals homozygous for the t allele are significantly underrepresented among prostate cancer patients, illustrating a protective role for the t allele in prostate carcinogenesis (Taylor et al., 1996; Hamasaki et al., 1999) . However, these findings have not been corroborated in later studies (Blazer et al., 2000; Habuchi et al., 2000) . Regarding breast cancer, both a tendency towards a decreased mortality rate in tt homozygote breast cancer patients (Lundin et al., 1999) as well as decreased risk in patients with the TT genotype (Schöndorf et al., 2003) have been reported. In our study, investigation of the TaqI site between affected and control individuals, however, did not reveal a difference between the frequencies of the genotypes. Lack of association between the TaqI alleles and breast cancer is in agreement with earlier (Dunning et al., 1999; Lundin et al., 1999) and recent reports (Hou et al., 2002; Newcomb et al., 2002; Schndorf et al., 2003) . The genotype frequencies in our breast cancer group are in concordance with the reports in the literature. However, the frequency of tt homozygotes in our control group is lower than reported by Schöndorf et al., 2003 . This difference may be due to the ethnic origin of populations.
The frequencies of T and t alleles were 61.5% and 38.5% (P = 0.058) in our patient group, while Curran et al. have reported allele frequencies of 64.0% and 36.0% (P = 0.053) and concluded that this indicated a significant difference between the patients and the control groups. However, in our opinion statistical significance at the 0.05 level provides no evidence that this polymorphism is associated with incidence of breast cancer.
In conclusion, we have not found any evidence that differences in the oncogenic properties of the VDR gene TaqI and BsmI alleles could confer a genetic predisposition to breast carcinogenesis. Comparing the patient group with the controls revealed no significantly increased risk for breast cancer patients carrying the TT or bb genotypes.
